Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 11 to 20 of 65 total matches.
In Brief: A New Breast Cancer Indication for Sacituzumab Govitecan (Trodelvy) (online only)
The Medical Letter on Drugs and Therapeutics • Mar 06, 2023 (Issue 1671)
platinum-based chemotherapy and a
programmed death receptor-1 (PD-1) or programmed
death-ligand 1 (PD-L1 ...
Sacituzumab govitecan-hziy (Trodelvy – Gilead) has
been approved for treatment of unresectable locally
advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2
(HER2)-negative breast cancer in adults who received
prior endocrine therapy and ≥2 additional systemic
therapies for metastatic disease. It was previously
approved for treatment-refractory metastatic triplenegative
breast cancer and for treatment of locally
advanced or metastatic urothelial cancer in adults
who received platinum-based chemotherapy and a
programmed death receptor-1...
Med Lett Drugs Ther. 2023 Mar 6;65(1671):e43-4 doi:10.58347/tml.2023.1671g | Show Introduction Hide Introduction
In Brief: Fam-trastuzumab deruxtecan (Enhertu) for Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
cancer in patients who
received prior chemotherapy for metastatic disease
or who developed disease ...
Fam-trastuzumab deruxtecan-nxki (Enhertu – Daiichi
Sankyo/AstraZeneca), which received accelerated
approval by the FDA in 2019 for treatment of HER2-positive breast cancer based on its rate and duration
of response,1 has been granted regular approval for
treatment of adults with unresectable or metastatic
HER2-positive breast cancer who received a prior
anti-HER2-based regimen in the metastatic setting or
in the neoadjuvant or adjuvant setting and developed
recurrence during or within 6 months of completing
treatment.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e60-1 doi:10.58347/tml.2023.1673f | Show Introduction Hide Introduction
Tisotumab Vedotin (Tivdak) for Cervical Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024 (Issue 1705)
cancer that progressed on or after chemotherapy. It
is the first antibody-drug conjugate to be approved ...
Tisotumab vedotin-tftv (Tivdak – Seagen/Genmab),
a tissue factor-directed antibody and microtubule
inhibitor conjugate, has received full approval from the
FDA for treatment of recurrent or metastatic cervical
cancer that progressed on or after chemotherapy. It
is the first antibody-drug conjugate to be approved
for treatment of cervical cancer. The drug received
accelerated approval from the FDA in 2021 for the
same indication.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):e109-10 doi:10.58347/tml.2024.1705g | Show Introduction Hide Introduction
Quizartinib (Vanflyta) for Acute Myeloid Leukemia (online only)
The Medical Letter on Drugs and Therapeutics • Oct 16, 2023 (Issue 1687)
,
and as maintenance monotherapy following
consolidation chemotherapy in adults with FLT3
internal tandem duplication ...
The FDA has approved the oral kinase inhibitor
quizartinib (Vanflyta – Daiichi Sankyo) for use
in combination with standard cytarabine and
anthracycline induction and cytarabine consolidation,
and as maintenance monotherapy following
consolidation chemotherapy in adults with FLT3
internal tandem duplication (ITD)-positive, newly-diagnosed
acute myeloid leukemia (AML).
Med Lett Drugs Ther. 2023 Oct 16;65(1687):e169-70 doi:10.58347/tml.2023.1687d | Show Introduction Hide Introduction
Tebentafusp (Kimmtrak) for Uveal Melanoma (online only)
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024 (Issue 1705)
. Patients were randomized to receive
tebentafusp or investigator-selected chemotherapy
(pembrolizumab ...
The FDA has approved tebentafusp-tebn (Kimmtrak –
Immunocore), a first-in-class bispecific gp100
peptide-HLA-directed CD3 T-cell engager, for
treatment of HLA-A*02:01-positive unresectable or
metastatic uveal melanoma in adults.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):e107-8 doi:10.58347/tml.2024.1705f | Show Introduction Hide Introduction
Sacituzumab Govitecan (Trodelvy) for Metastatic Triple-Negative Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
conjugate to become available in
the US.
Standard Treatment – Sequential single-agent
chemotherapy ...
The FDA has approved sacituzumab govitecan-hziy
(Trodelvy – Immunomedics), a trophoblast cell-surface
antigen-2 (Trop-2)-directed antibody and topoisomerase
inhibitor conjugate, for treatment of adults with metastatic
triple-negative breast cancer who have received ≥2 prior
therapies for metastatic disease. It is the first Trop-2-directed antibody-drug conjugate to become available in the US.
In Brief: A New Prostate Cancer Indication for Olaparib (Lynparza) (online only)
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
)-negative, high-risk
early breast cancer who received prior neoadjuvant
or adjuvant chemotherapy.1 It had ...
The oral poly(ADP-ribose) polymerase (PARP)
inhibitor olaparib (Lynparza – AstraZeneca) has now
been approved by the FDA for use in combination
with abiraterone (Zytiga, and others) and either
prednisone or prednisolone for treatment of adults
with deleterious or suspected deleterious BRCA-mutated
(BRCAm) metastatic castration-resistant
prostate cancer (mCRPC). Olaparib was previously
approved by the FDA for treatment of adults with
deleterious or suspected deleterious germline or
somatic homologous recombinant repair (HRR) genemutated
mCRPC who progressed on prior treatment
with...
Med Lett Drugs Ther. 2023 Jun 26;65(1679):e106-7 doi:10.58347/tml.2023.1679g | Show Introduction Hide Introduction
Amivantamab (Rybrevant) for Non-Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
chemotherapy. It is the first bispecific antibody
to become available in the US for this indication ...
Amivantamab-vmjw (Rybrevant – Janssen), an EGFR-MET
bispecific antibody, has received accelerated
approval from the FDA for IV treatment of locally
advanced or metastatic non-small cell lung cancer
(NSCLC) with epidermal growth factor receptor
(EGFR) exon 20 insertion mutations in adults whose
disease has progressed on or after platinum-based
chemotherapy. It is the first bispecific antibody
to become available in the US for this indication.
Accelerated approval of the drug was based on the
overall response rate and duration of response.
Margetuximab (Margenza) for HER2-Positive Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022 (Issue 1664)
(Margenza – MacroGenics), a HER2/neu receptor antagonist,
for use in combination with chemotherapy ...
The FDA has approved margetuximab-cmkb
(Margenza – MacroGenics), a HER2/neu receptor antagonist,
for use in combination with chemotherapy
for treatment of metastatic human epidermal growth
factor receptor 2 (HER2)-positive breast cancer in
adults who received ≥2 prior anti-HER2 regimens, at
least one of which was for metastatic disease.
Mobocertinib (Exkivity) for Non-Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022 (Issue 1664)
insertion
mutations in adults whose disease has progressed on
or after platinum-based chemotherapy ...
Mobocertinib (Exkivity – Takeda), an oral kinase
inhibitor, has received accelerated approval from the
FDA for treatment of locally advanced or metastatic
non-small cell lung cancer (NSCLC) with epidermal
growth factor receptor (EGFR) exon 20 insertion
mutations in adults whose disease has progressed on
or after platinum-based chemotherapy. Accelerated
approval was based on the overall response rate and
duration of response. Mobocertinib is the second
drug to become available in the US for this indication;
the IV EGFR-MET bispecific antibody amivantamab
(Rybrevant) was approved...